AbCellera Biologics Inc.
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
ABCL$12.46-0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(Expressed in thousands of U.S. dollars.)
| Three months ended March 31, | ||
|---|---|---|
| 2024 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(40,610) | $(45,621) |
| Cash flows from operating activities: | ||
| Depreciation of property and equipment | 3,155 | 4,409 |
| Amortization of intangible assets | 1,689 | 922 |
| Amortization of operating lease right-of-use assets | 1,922 | 1,274 |
| Stock-based compensation | 17,409 | 14,786 |
| Fair value gain on contingent consideration and other | 1,707 | 2,213 |
| Changes in operating assets and liabilities: | ||
| Research fees and grants receivable | (18,576) | (1,133) |
| Income taxes payable | (3,182) | (4,408) |
| Accounts payable and accrued liabilities | (4,878) | (3,409) |
| Deferred revenue | (8,017) | 13,313 |
| Deferred grant income | 11,278 | (1,220) |
| Other assets | (3,605) | 7,320 |
| Net cash used in operating activities | (41,708) | (11,554) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (24,140) | (10,636) |
| Purchase of marketable securities | (249,371) | (164,990) |
| Proceeds from marketable securities | 306,545 | 190,027 |
| Receipt of grant funding | 7,168 | 1,018 |
| Long-term investments and other assets | (4,385) | (5,601) |
| Investment in equity accounted investees | (5,907) | (1,883) |
| Net cash provided by investing activities | 29,910 | 7,935 |
| Cash flows from financing activities: | ||
| Payment of liability for in-licensing agreement and other | (185) | (178) |
| Proceeds from long-term liabilities and exercise of stock options | 3,016 | 6,148 |
| Net cash provided by financing activities | 2,831 | 5,970 |
| Effect of exchange rate changes on cash and cash equivalents | (781) | 590 |
| Increase (decrease) in cash and cash equivalents | (9,748) | 2,941 |
| Cash and cash equivalents and restricted cash, beginning of period | 160,610 | 183,615 |
| Cash and cash equivalents and restricted cash, end of period | $150,862 | $186,556 |
| Restricted cash included in other assets | 2,290 | 2,290 |
| Total cash, cash equivalents, and restricted cash shown on the balance sheet | $148,572 | $184,266 |
| Supplemental disclosure of non-cash investing and financing activities | ||
| Property and equipment in accounts payable | 18,654 | 10,960 |
| Right-of-use assets obtained in exchange for operating lease obligation | 107 | 3,361 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.